Sum­mit ex­ecs sharp­en the bud­get ax as Duchenne MD study flops — shares rout­ed at Sarep­ta part­ner

Sum­mit Ther­a­peu­tics $SMMT has crushed high ex­pec­ta­tions for its Duchenne mus­cu­lar dy­s­tro­phy drug, re­port­ing to­day that their ther­a­py com­plete­ly failed a key tri­al. Ex­ecs at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER